Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
AML survivors treated with blood or marrow transplantation have a greater risk of grade 3 or higher chronic health conditions, according to a survey that compared the long-term outcomes between survivors and their healthy siblings.
Data from an ongoing trial of luspatercept, an erythroid maturation agent, in patients with myelofibrosis and anemia shows promise of clinically significant activity with low level of grade 3/4 adverse effects.
Using a computational approach, researchers detected the effect of dietary changes and antibacterial therapies on gut microbiota of patients who had undergone allo-HSCT, which may be associated with adverse events such as GVHD.